EIKN (Eikon Therapeutics) OCF Margin %: 0.00% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

EIKN Eikon Therapeutics Inc EIKN
12 GF Score
Price $9.84
View Full Analysis

What is Eikon Therapeutics OCF Margin %?

Eikon Therapeutics EIKN -3.40% 12 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates EIKN with a GF Score™ of 12/100. Among 950 Biotechnology companies, Eikon Therapeutics ranks worse than 105263.05% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Eikon Therapeutics's Cash Flow from Operations for the three months ended in Mar. 2026 was $-89.80 Mil. Eikon Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Eikon Therapeutics's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Eikon Therapeutics's current OCF Yield % is -24.69%.

The historical rank and industry rank for Eikon Therapeutics's OCF Margin % or its related term are showing as below:


EIKN's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -64.565
* Ranked among companies with meaningful OCF Margin % only.

Eikon Therapeutics OCF Margin % Related Terms

Eikon Therapeutics OCF Margin % Historical Data

* Premium members only.

The historical data trend for Eikon Therapeutics's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eikon Therapeutics OCF Margin % Chart

Eikon Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
OCF Margin %
0.00 0.00 0.00

Eikon Therapeutics Quarterly Data
Dec23 Dec24 Mar25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
EIKN
12GF Score
Eikon Therapeutics Inc EIKN
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eikon Therapeutics OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Eikon Therapeutics's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-188.516/0
= %

Eikon Therapeutics's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-89.801/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Eikon Therapeutics (EIKN) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Eikon Therapeutics and its competitors. According to the industry distribution chart, Eikon Therapeutics ranks #999999 out of 950 companies in the Biotechnology industry.
Is Eikon Therapeutics' OCF Margin % too high?
Eikon Therapeutics' current OCF Margin % is 0.00%. Based on the distribution chart, Eikon Therapeutics ranks #999999 out of 950 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Eikon Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Eikon Therapeutics' OCF Margin % compare to PRME and CRMD?
According to the Biotechnology industry distribution chart, Eikon Therapeutics ranks #999999 out of 950 companies for OCF Margin %. This places Eikon Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Eikon Therapeutics and its competitors. Eikon Therapeutics's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eikon Therapeutics stock overvalued right now?
Eikon Therapeutics (EIKN) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Eikon Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Eikon Therapeutics (EIKN), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Eikon Therapeutics Business Description

Address 230 Harriet Tubman Way, Millbrae, CA, USA, 94030
Eikon Therapeutics Inc is a late-stage clinical biopharmaceutical company dedicated to building a world-wide , fully-integrated organization developing important, medicines to address serious unmet medical needs. It operates in a single operating segment, which is in the business of drug discovery leveraging its proprietary technology and clinical development of its product candidates. Its product candidates include: EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006.
12GF Score

Get the complete analysis for EIKN

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.84
Price